Researchers reported promising preliminary outcomes for the first four children enrolled in
a U.S. gene therapy trial for Wiskott - Aldrich syndrome (WAS), a life - threatening genetic blood and immune disorder, at the 57th annual meeting of the American Society of Hematology.
Not exact matches
AveXis, Inc., a clinical - stage
gene therapy company developing treatments for patients suffering from rare and life - threatening neurological genetic diseases, announced in July 2016 that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the treatment based on preliminary clinical results from the trial of AVXS
therapy company developing treatments for patients suffering from rare and life - threatening neurological genetic diseases, announced in July 2016 that the
U.S. Food and Drug Administration (FDA) granted Breakthrough
Therapy Designation for the treatment based on preliminary clinical results from the trial of AVXS
Therapy Designation for the treatment based on preliminary clinical results from the
trial of AVXS - 101.
The proposed clinical
trial, in which researchers would use CRISPR to engineer immune cells to fight cancer, won approval from the Recombinant DNA Advisory Committee (RAC) at the
U.S. National Institutes of Health, a panel that has traditionally vetted the safety and ethics of
gene therapy trials funded by the
U.S. government and others.
The
U.S. Food and Drug Administration (FDA) has begun proceedings that could disqualify
gene therapy researcher James Wilson of the University of Pennsylvania in Philadelphia from conducting any future clinical
trials.
This led the team to package the
gene editing tool into AAV, used in late - phase clinical
trials in the
U.S. and also already approved in a
gene therapy drug in the European Union.
Weill Cornell is the birthplace of many medical advances — including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo - biopsy pregnancy and birth in the
U.S., the first clinical
trial of
gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain - injured patient.